
usd feb pm et
summari compani provid medic product servic primarili area orthoped
medic surgic medsurg well neurotechnolog spine
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan stock trade
see sale growth
follow growth despit syk
recent merger integr activ
compani achiev continu oper
margin expans recent year expect
achiev anoth basi point
margin expans exclud
impact
acquisit expect close
anticip competit strength
syk mako robot continu drive share
gain tradit stabl knee
hip replac market
approxim mako placement
competit account
decemb
mako robot instal global
decemb almost
instal alon given
orthoped practic
think signific room grow
novemb agre acquir
enterpris valu think
chose opportun time acquir
share beaten
distributor issu liquid
share trade
ep attract valu
see long-term strength orthoped
busi continu roll mako
aid recent weak
primari competitor zimmer biomet
manufactur complianc issu
addit believ pend
acquisit substanti bolster
presenc extrem procedur
divestitur satisfi anti-trust concern
also view favor larg
diversifi supplier reput medic
devic suppli make prefer
vendor hospit industri
consolid late
risk recommend target
competit failur integr acquisit
slowdown procedur growth
target reflect
multipl ep
estim multipl peer
sustain above-market
organ growth driven increasingli
oper competit area global
medic devic industri character rapid
technolog innov market share volatil
medical/surg suppli unit may vulner
reduct hospit capit equip spend
demand orthoped product becom
less immun econom cycl
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president global
corpor overview corp one world lead medic technolog compani
compani offer innov product servic orthopaed revenu medic
surgic neurotechnolog spine aim improv patient hospit
orthopaed segment consist primarili implant use hip knee joint replac
trauma extrem surgeri goal deliv advanc implant design special
instrument make orthopaed surgeri recoveri simpler faster effect artifici
joint made cobalt chromium titanium alloy ceram ultra-high molecular weight
polyethylen implant patient whose natur joint damag arthriti
osteoporosi diseas injuri also sell trauma-rel product use primarili
fixat fractur result sudden injuri includ intern fixat devic nail plate
screw extern fixat devic pin wire connect bar receiv
clearanc unit state food drug administr fda mako total knee applic
robotic-arm assist technolog complet full commerci launch one four
lead global competitor joint replac trauma extrem product three
inc depuy synth johnson johnson compani smith nephew
medic surgic medsurg segment product includ surgic equip navig
system instrument endoscop commun system endoscopi patient handl
emerg medic equip intens care dispos product medic reprocess
remanufactur medic devic sustain medic devic product use varieti
medic specialti mani competitor medsurg segment launch
next gener set power tool compris sagitt saw reciproc saw rotari drill
neurotechnolog spine product includ neurosurg neurovascular spinal implant devic
neurotechnolog offer includ product use minim invas endovascular techniqu
comprehens line product tradit brain open skull base surgic procedur
orthobiolog biosurgeri product includ synthet bone graft vertebr augment
product minim invas product treatment acut ischem hemorrhag stroke
one five lead global competitor neurotechnolog four johnson
 johnson terumo corpor inc one five lead global competitor spine
four sofamor danek inc subsidiari depuy synth
inc globu medic inc
corpor strategi seek achiev sale growth high-end medic technolog
med-tech industri maintain capit alloc strategi priorit acquisit
dividend share repurchas invest million acquisit paid
million dividend repurchas million share success acquisit
tend small rel market capit
novemb acquir global leader complex spine minim
invas solut billion februari acquir entellu medic medic technolog
compani make product design minim invas treatment variou ear nose throat
diseas state million septemb also acquir novadaq technolog inc
lead develop fluoresc imag million
impact major develop novemb announc enter definit
agreement acquir per share equiti valu reflect
premium price market close novemb well-posit support
wmgi busi due strength syk commerci organ financi well-being howev
believ could regulatori pushback deal may requir asset divestitur
appeas expect deal close
august initi voluntari product recal involv specif lot product
respons warn letter receiv food drug administr fda resum
ship product return full suppli capac end product manufactur
intens care dispos product acquir billion
financi trend achiev compound annual growth rate compound-annual-growth-rate revenu five
year end includ benefit sever acquisit revenu grew
year-over-year billion typic invest revenu research
develop spent million decemb quarter
moder net debt total capit low leverag debt ebitda ratio
gener posit cash flow oper least past five year billion
given financi posit see near-term difficulti compani pursu
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc decemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
lift target multipl
ep estim multipl high end
rang expect acceler growth due compani
improv competit posit ep vs higher
estim rais ep lift
ep sale increas organ billion
organ sale volum grew off-set due lower price organ
basi sale orthopaed segment grew year-over-year medsurg
neurotechnolog spine instal mako robot global
vs prior-year period syk manag refer strong healthi
order book mako robot multipl time give us confid mako robot
placement sustain momentum overal result expect
maintain buy rate /kevin huang cfa
pm et cfra keep buy opinion share stryker corpor
lift target
ep estim multipl high end
three-year rang compani improv competit posit
ep vs higher estim lift
ep initi ep sale increas
organ billion driven primarili higher sale volum
off-set slightli lower price organ basi sale
orthopaed segment grew year-over-year medsurg
neurotechnolog spine report growth neurotechnolog
spine busi driven acquisit novemb
move quickli integr manag aim establish
align organ end mako robot except
strong quarter placement mako robot global
vs placement /kevin huang cfa
analyst research note compani news
et cfra reaffirm buy opinion share stryker corpor
rais target price base
multipl ep estim multipl exce
syk rang due syk strengthen
competit posit orthoped market ep vs beat
estim lower ep
initi ep organ basi sale grew yoy
expect syk out-performance driven sustain
strength knee growth extrem strong placement mako
robot global vs despit
fda approv zimmer biomet rosa knee system approxim
mako placement competit account
think well-posit continu take market
share hip knee replac market still expect
close acquisit /kevin huang cfa
et cfra keep hold opinion share
morn announc enter definit
agreement acquir per share
reflect premium price market close novemb
merger would significantli boost market share orthoped
product extrem surgeri particularli upper extrem
shoulder elbow wrist hand procedur think chosen
opportun time acquir share beaten
recent distributor issu liquid concern well-posit
support busi due strength commerci organ
financi well-being howev believ could regulatori
pushback deal may requir asset divestitur appeas lift
price target share reflect announc
deal expect close /kevin huang cfa
et cfra keep buy opinion share stryker corpor
lift target price base
multipl ep estim multipl
exce rang due strengthen
competit posit orthoped market ep vs
land higher estim lift ep
ep sale grew organ
billion organ basi orthopaed sale grew yoy medsurg
neurotechnolog spine impress mako robot
placement made expect placement
prior-year period meanwhil mako total knee arthroplasti
procedur increas yoy call manag express
confid achiev continu low double-digit earn growth
sum impress quarter live high expect
reiter buy opinion /kevin huang cfa
et cfra reiter buy opinion share stryker corpor
lift target base multipl
ep multipl peer
sustain above-market organ growth driven increasingli strong
competit posit ep vs higher
estim lift ep ep
sale grew organ billion organ
basi orthopaed sale grew yoy medsurg neurotechnolog
spine continu see market share gain knee replac
driven mako robot sale increas robot util believ
success mako knee procedur enabl compani achiev
share gain histor stabl hip replac market mako hip
procedur grew doubl digit total mako procedur grew
approxim year-over-year approxim led
growth mako knee procedur /kevin huang cfa
et cfra keep buy opinion share stryker corpor
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
